Human Reproduction Update Advance Access originally published online on February 7, 2008
Human Reproduction Update 2008 14(3):289-291; doi:10.1093/humupd/dmm051
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Reply: Is it time for meta-analysis?
1 Department of Reproductive Medicine, St Mary's Hospital, CMMC University Hospitals, Whitworth Park, Manchester M13 0JH, UK 2 Department of Obstetrics and Gynaecology, Lancashire Teaching Hospitals, Preston, UK
3 Correspondence address. Fax: +44-0161-224-0957; E-mail: luciano.nardo@cmmc.nhs.uk
| The first 10% of the full text of this article appears below. |
Sir,
In their letter, Dr Ruopp and co-authors question the statistical approach and the validity of our meta-analysis on the use of low-dose aspirin in women undergoing in vitro fertilization (IVF) (Gelbaya et al., 2007
). They also go some way to suggest that we have reached a flawed interpretation of the results. Their argument is that random-effects models have an inherent loss of precision by introducing an in-between study variance and that random-effects model should only be used when the absence of inter-study heterogeneity can be assumed.
With fixed-effects models, it is assumed that there is a sole common effect estimates for all studies, i.e. the true effect of treatment, in both magnitude and